依达拉奉治疗血管性帕金森综合征的疗效观察  

Effect of Edaravone on treating vascular parkinsonism

作　　者：王冰[1] 

机构地区：[1]郑州大学公共卫生学院,郑州450000

出　　处：《中国实用神经疾病杂志》2007年第9期45-46,共2页Chinese Journal of Practical Nervous Diseases

摘　　要：目的评定依达拉奉治疗血管性帕金森综合征的临床疗效。方法入选85例病人,随机分为治疗组45例、对照组40例,2组病人诊断符合血管性帕金森综合征的诊断标准,年龄、性别、症状、体征及病程等具有可比性。对照组给予美多巴片,疗程12周;治疗组给予依达拉奉注射液、美多巴片,疗程12周。12周后观察临床疗效。结果依达拉奉组疗效明显优于美多巴组。结论依达拉奉治疗血管性帕金森综合征效果满意,有应用价值。Objective To assess the curative effect of Edaravone in the treatment of vascular parkinsonism. Methods In a randomized trial,85 patients without contraindication were divided into treatment group（45 patients treated with Edaravone injection 80mg,qd, and routine therapy） and control group（40 patients treated with routine therapy, Madopar,qd, po）, there were comparabilities with general condition before treatment between the two groups above. Results After treatment, control group＇s UPDRS evidently decreased（P〈0. 05）. Conclusion Edaravone can provide a satisfactory treatment for patients with vascular parkinsonism.

关 键 词：血管性帕金森综合征 依达拉奉 美多巴 疗效观察 

分 类 号：R742.5[医药卫生—神经病学与精神病学]